| Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2013: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2012: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2011: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Research Abstract |
Preclinical evaluations for the development of a novel anti-tumor invasion medicine by utilization of 5-(N-ethyl-N-isopropyl)-amiloride (EIPA) which had exhibited promising potential in vitro were performed, aiming at developing a novel powerful therapy against gliomas of which treatment has long been unimproved. On the way of the explorations of modes of action of EIPA, a characteristic blood vessel was found to contribute to the glioma cell invasions, and an implication that activation process of TGFbeta1 may participate in this step was obtained. Furthermore, the validity to consider EIPA as an anti-tumor invasion medicine was confirmed from the observation of contributions of the target of EIPA sodium ion/proton exchanger1 (NHE1) on lymph node metastasis of head and neck squamous cell carcinoma cells (SCC). Highly metastatic subline-cell of a SCC acquired enhanced expression of NHE1 compared with the non-metastatic parental cell line, and knockdown of NHE1 reduced the metastasis.
|
